These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24053398)

  • 1. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
    Jorquera PA; Anderson L; Tripp RA
    Expert Rev Vaccines; 2016; 15(2):173-87. PubMed ID: 26641318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus: how, why and what to do.
    Rodriguez R; Ramilo O
    J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSV--a substantial slice of the airway disease burden and the way to a vaccine.
    Weigl JA
    Paediatr Int Child Health; 2012 Nov; 32 Suppl 2():S9-15. PubMed ID: 23394753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying targets in the hunt for effective respiratory syncytial virus interventions.
    Tayyari F; Hegele RG
    Expert Rev Respir Med; 2012 Apr; 6(2):215-22. PubMed ID: 22455493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive and therapeutic strategies for respiratory syncytial virus infection.
    Vujovic O; Mills J
    Curr Opin Pharmacol; 2001 Oct; 1(5):497-503. PubMed ID: 11764776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA; Wald ER
    Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs and treatment for respiratory syncytial virus.
    Maggon K; Barik S
    Rev Med Virol; 2004; 14(3):149-68. PubMed ID: 15124232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.